復星醫藥大舉收購印度同行

Shanghai Fosun Pharma has agreed to pay $1.1bn for an 86 per cent stake in Indian drugmaker Gland Pharma, in the largest Indian corporate takeover by a Chinese company.

上海復星醫藥(Shanghai Fosun Pharmahas)同意斥資11億美元收購印度製藥商Gland Pharma 86%的股權，這是中國企業收購印度企業規模最大的一筆交易。

The deal is the biggest acquisition by Hong Kong-listed Fosun since the mysterious disappearance for several days last year of Guo Guangchan, the group’s chairman, in connection with an anti-corruption investigation in China.

該交易是在香港上市的復星集團(Fosun)自去年董事長郭廣昌神祕失蹤數天以來最大的一筆收購。郭廣昌失聯與中國一項反腐調查有關。

Yesterday’s deal — which values Gland at $1.35bn — also provides a lucrative exit for private equity firm KKR, which three years ago paid $200m for a 38 per cent stake in the Hyderabad-based drugmaker and is selling its full holding.

昨日交易對Gland估值13.5億美元，它也讓私人股本集團KKR能夠盈利退出，後者3年前用2億美元收購了這家總部位於海德拉巴的製藥商38%的股份，此次出售其全部持股。